| Latest Forum Topics / QT Vascular |
 Post Reply
|
|
Light at the end of the tunnel
|
|||||
|
SureStrike
Veteran |
17-Dec-2021 14:00
|
||||
|
x 0
x 0 Alert Admin |
Q more @4. Good luck to me! DYODD 😂 🤣
|
||||
| Useful To Me Not Useful To Me | |||||
|
lucskywalker
Senior |
17-Dec-2021 13:36
|
||||
|
x 0
x 0 Alert Admin |
wah buy buy buy | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SureStrike
Veteran |
17-Dec-2021 13:29
|
||||
|
x 0
x 0 Alert Admin |
UPDATE ON CHOCOLATE TOUCH® US PIVOTAL STUDY Key Points:
SINGAPORE, 17 December 2021 &ndash QT Vascular Ltd., (the &ldquo Company&rdquo or &ldquo QT Vascular&rdquo , and together with its subsidiaries, the &ldquo Group&rdquo ), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease. The Board of Directors (&ldquo Board&rdquo ) of the Company refers to its announcements dated 13 July 2020, 27 August 2020 and 30 August 2020 in relation to the proposed disposal of the Sale Asset which includes Chocolate Touch® Paclitaxel-Coated PTA Balloon Catheter by the Group to G Vascular Private Limited (&ldquo G Vascular&rdquo ). The Company is pleased to announce that the Company&rsquo s subsidiary, TriReme Medical, LLC (&ldquo TML&rdquo ), has, under the terms of the definitive asset purchase agreement entered into with G Vascular announced on 27 August 2020, completed the analysis of 12-month post-procedure clinical data from the United States pivotal study of the Chocolate Touch® Paclitaxel-Coated PTA Balloon Catheter. A randomized controlled trial evaluating the Company&rsquo s Chocolate Touch® drug-coated balloon (&ldquo DCB&rdquo ) in symptomatic patients having femoro-popliteal arterial disease (&ldquo Chocolate Touch® Pivotal Trial&rdquo or &ldquo Trial&rdquo ) was conducted. The global, multicenter study originally planned to cover randomized patients 1:1 to receive either the Chocolate Touch® or the Lutonix® DCB (a DCB device commercialized by Becton, Dickinson and Company). The Chocolate Touch® Pivotal Trial&rsquo s CoPrincipal Investigators are Dr. Thomas Zeller of Universitaets-Herzzentrum Freiburg-Bad Krozingen, and Dr. Mehdi Shishehbor of University Hospitals Cleveland Medical Center. The Chocolate Touch® Pivotal Trial was performed with the support of multiple professional parties to ensure the highest level of data. The Trial included clinical events committee and angiographic core laboratory managed by Yale University Cardiovascular Research Center, and an external ultrasound QT VASCULAR LTD. Page 2 of 3 core laboratory to assess clinical outcomes. The Trial&rsquo s primary efficacy endpoint was true DCB success at 12 months post-procedure. The primary safety endpoint was freedom from major adverse events at 12 months post-procedure. A total of 313 patients were randomized to Chocolate Touch® (n=152) vs Lutonix DCB (n=161). TML is currently in the process of finalizing its submission to the United States Food and Drug Administration (&ldquo FDA&rdquo ) for pre-market approval (&ldquo PMA&rdquo ) of Chocolate Touch® . The submission to the FDA is expected later this month. As at the date of this announcement, G Vascular has paid US$5.9 million (which comprised Closing Payment of US$4.9 million and assumed liabilities of US$1 million) to the Company and has made the necessary investment to progress the Trial and will continue to do so to obtain PMA approval from FDA for Chocolate Touch® . The completion of the analysis of the 12-month post-procedure clinical data of the Chocolate Touch® Pivotal Trial, which is expected to be the last major item required for FDA submission of a PMA, is a significant step towards unlocking the post-closing payment of at least US$16.1million from G Vascular, for the Company&rsquo s shareholders as indicated in the Company&rsquo s circular to shareholders in relation to the disposal of Chocolate Touch® to G Vascular dated 13 July 2020. The post-closing payment will be unlocked either upon sale of Chocolate Touch® asset to other parties or commercial sale of Chocolate Touch® after PMA of Chocolate Touch® has been received. |
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
17-Dec-2021 13:25
|
||||
|
x 0
x 0 Alert Admin |
UPDATE ON CHOCOLATE TOUCH® US PIVOTAL STUDY Key Points: The clinical report with 12 months post-procedure analysis of the primary endpoints for Chocolate Touch® Pivotal Trial is expected to be the last major item required for FDA submission of a PMA application Marks significant step toward unlocking the post-closing payment from G Vascular of at least US$16.1 million for shareholders |
||||
| Useful To Me Not Useful To Me | |||||
|
Sunstar
Senior |
17-Dec-2021 13:24
|
||||
|
x 0
x 0 Alert Admin |
MW and Christian kwok know they cannot win. Too much bad publicity about them in incredible holdings, and penny stock in Malaysia. And also the existing shareholders up their stake by another 10% to challenge MW. Best not to stand in front of a stampeding elephant exiting | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Sunstar
Senior |
17-Dec-2021 13:19
|
||||
|
x 0
x 0 Alert Admin |
I already forewarn .. who else can dump 50m shares today ? It will be interesting to watch substantial shareholder announcement from sgx.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Goodgoing
Master |
17-Dec-2021 12:20
|
||||
|
x 0
x 0 Alert Admin |
Another junk penny, waste time to monitor this junk counter lead by the poor performance CEO.
|
||||
| Useful To Me Not Useful To Me | |||||
|
lucskywalker
Senior |
17-Dec-2021 12:09
|
||||
|
x 0
x 0 Alert Admin |
Where is SKLONG? | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
GoodLearner
Senior |
17-Dec-2021 11:59
|
||||
|
x 0
x 0 Alert Admin |
Can' t see much support at 0.004
|
||||
| Useful To Me Not Useful To Me | |||||
|
MakeChanges
Elite |
17-Dec-2021 07:45
Yells: "No price is too low for a bear or too high for a bull" |
||||
|
x 0
x 0 Alert Admin |
Drama company
|
||||
| Useful To Me Not Useful To Me | |||||
|
waitlonglong2011
Senior |
17-Dec-2021 00:29
|
||||
|
x 0
x 0 Alert Admin |
In the end, what was supposed to be a boardroom tussle which got some investors excited, never happened. Instead Kwok and Yip sold out of DVM, less than three weeks after they had bought in. < --- only 1 man we saw for this round and he is trying to call in more people to follow him!
|
||||
| Useful To Me Not Useful To Me | |||||
|
tedlim
Veteran |
16-Dec-2021 22:08
|
||||
|
x 0
x 0 Alert Admin |
Old news but provide some insights on the Christian Kwok-Leun Yau Heilesen Story behind penny stock crash Published: Saturday May 3, 2014 MYT 12:00:00 AM BY YVONNE TAN https://www.thestar.com.my/business/business-news/2014/05/03/story-behind-penny-stock-crash/ THIS week& rsquo s crash of four small-cap stocks which dented sentiment across the local bourse has the market abuzz about a foreign market personality by the name of Christian Kwok-Leun Yau Heilesen (pic). Kwok, the founder of Hong Kong-based mobile content developer Funmobile Holdings Ltd, is no stranger to the local market. Hailing from Copenhagen, the 30-year-old Dane has been emerging as a substantial shareholder in various small, mostly loss-making tech firms listed on Bursa Malaysia from as far back as 2011. Coincidentally, the stock prices of these companies always sky-rocketed after his emergence and fell back flat after he sold out, sometimes in just a matter of weeks. This time round, the four stocks which crashed were Visdynamics Holdings Bhd,MNC Wireless Bhd, Solution Engineering Holdings Bhd and Industronics Bhd. On Monday, all four, which had been on a general uptrend for some time, crashed, with MNC losing the most value in terms of percentage, falling by 60%. Now, Kwok is again being bandied about by stock dealers as the common person involved in all four stocks. Apparently, the four companies each had a block of shares that had been rolled over a few times with & ldquo no real money& rdquo coming in to pick up the blocks. Dealers say the bubble finally burst after one stockbroking house, among several, stopped the line of credit. As far as links between the firms go, Solution Engineering is 10.8% owned by Industronics, an electronics company of which Kwok was the chairman from April 2013 to June 2013. While the market is still trying to connect the dots, Kwok has openly come out to say that he had divested his investments in Malaysia several months ago. & ldquo I have not been to Malaysia for several months now ... I sold all my investments several months ago to investors from Macau,& rdquo Kwok told StarBiz when contacted on Tuesday. Meanwhile, the buzz among those in the market does not stop here. In a seemingly related event which took place last year, a CEO of a public-listed firm had a major falling out with his broker. & ldquo This event had resulted in investigations being made and basically opened a can of worms which led to the gradual departure of a few active traders from the country,& rdquo one seasoned dealer reveals. Interestingly, Kwok& rsquo s departure from Malaysia was not well-publicised although his emergence a few years back in the local market was accompanied by much fanfare. The broker reveals that this week& rsquo s crash of these four stocks & ndash which were all in the red as at yesterday& rsquo s close except for Solution Engineering which ended flat & ndash had resulted in some RM40mil in losses for remisiers from brokerages across the country, Kwok first emerged in Malaysia in 2011 with Raymond Yip Wai Man, a Hong Kong citizen, and reportedly bought a 15% stake in DVM Technology Bhd. They had then asked for an EGM to remove several directors from the company. In the end, what was supposed to be a boardroom tussle which got some investors excited, never happened. Instead Kwok and Yip sold out of DVM, less than three weeks after they had bought in. Not long after that, DVM& rsquo s share price plunged to 13.5 sen after reaching 25 sen earlier, its highest in five years. A couple of months after that, Kwok emerged in another local IT firm, GPRO Technologies Bhd, where the stock price surged after his emergence. He was appointed executive chairman of the company but has since ceased to be a substantial shareholder. In March 2012, Kwok surfaced in Cybertowers Bhd, once again sending the firm& rsquo s share price flying high and then hitting limit-down in a relatively short span of time. Kwok sold his entire 8.3 million share block in Cybertowers less than five months after he emerged as a substantial shareholder in the company which is involved in automated vehicle locating systems. More legs for small-caps Meanwhile, the crash of the four stocks has evidently affected sentiment on penny stocks on Bursa Malaysia although experts feel that it is not time to be too concerned. Fundamentally, market experts agree that the FTSE Bursa Malaysia Small Cap Index, which tracks smaller companies, has become pricey at 11.5 times 2014 price earnings (PE), having run up for at least the past 18 months. Any profit-taking at the moment is healthy, they say. & ldquo The recent crash is probably an isolated case but sends a signal that traders should be cautious,& rdquo says a senior market analyst. The index has lost some 400 points from its all-time high of 17,867 points reached last Tuesday, due to this week& rsquo s selldown. While the pause in the rally may continue for a while buoyed by the & ldquo sell in May& rdquo factor and the World Cup in June, it still has legs and should continue, moving on, some analysts predict. & ldquo Going forward, we may see the continuity of & ldquo a tale of two markets& rsquo whereby large-cap stocks will continue to trade sideways with limited upside, while small- and mid-cap stocks could extend their rally after May and June,& rdquo JF Apex Securities tells clients. The benchmark FTSE Bursa Malaysia KLCI which tracks the 30 largest firms on Bursa Malaysia remains one of the indexes with the richest valuations in the region, trading at more than 16 times 2014 PE. & ldquo We advise investors to be selective on small-cap stocks by looking at fundamentally-sound companies.& rdquo JF Apex adds. |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Joelton
Supreme |
16-Dec-2021 09:44
|
||||
|
x 0
x 0 Alert Admin |
QT Vascular shareholders vote to remove incumbent directors third EGM being sought to appoint new directors
QT Vascular $ QT Vascular: 5I0 -16.67% shareholders voted on Wednesday (Dec 15) to remove the company' s incumbent directors at an extraordinary general meeting (EGM), although the result will be contentious given that an earlier announcement, dated Dec 11, had questioned the validity of the resolutions.
According to the requisitioning shareholders, 58.1 per cent of votes cast were in approval of resolutions to remove Mimon Brosh, Sho Kian Hin and Ng Boon Eng as directors of the company.
A total of 603.9 million votes were counted. The company had 2.3 billion shares outstanding as at Dec 10.
This latest twist comes after the same requisitioning shareholders, consisting of a company called Mission Well and an individual named Tansri Saridju Benui, had tried to install nominees of their own in QT Vascular' s board at an EGM on Dec 6. But these resolutions were defeated, with 49.8 per cent of shareholders voting for it. A total of 559.3 million votes were counted at that EGM.
Mission Well owned a 10.2 per cent stake in the company as of Nov 16, or a total of 231.4 million shares, while Tansri Saridju Benui owned 50,000 shares.
QT Vascular had previously said Wednesday' s EGM could not be validly held, since an approval of all resolutions would leave the company without any directors and put it in breach of both the company' s constitution and the Companies Act. The company also said that its directors would not attend the meeting.
In an email sent after the vote to QT Vascular' s chief financial officer Kelvin Tong, and which was seen by The Business Times, Christian Kwok-Leun Yau Heilesen said the result was a " clear indication" of a lack of confidence in the company' s current management.
Heilesen, who is Mission Well' s director, also said that requisitioning shareholders would proceed to convene a third EGM to appoint new directors. He requested a copy of the company' s shareholder list by Dec 17. If the incumbents fail to provide the list, Heilesen also said the requisitioning shareholders would take necessary legal action to protect their interests.
" The incumbent directors' repeated attempts at obstructing and delaying the calling of the further EGM, especially now that their removal is impending, is clearly opportunistic and prejudicial to the interest of the company' s shareholders," Heilesen said.
In a bourse filing on Monday (Dec 13) night, QT Vascular said it may apply to the High Court for formal guidance on another EGM that Mission Well and Benui are seeking -- to try again to appoint their own nominees as directors. (see amendment note)
The company also said it " will not recognise" any attempt by the requisitioning shareholders to hold a second vote and urged other shareholders to not recognise it as well.
The incumbent directors also plan to issue new shares to repay US$1 million of debt to creditors, including former chief executive Eitan Konstantino as well as 2 entities: MDIE and Emerald Apex.
The additional shares would represent 10.3 per cent of QT Vascular' s enlarged share capital, and could tip the balance of voting power against the requisitioning shareholders who are trying to oust the existing board.
|
||||
| Useful To Me Not Useful To Me | |||||
|
MakeChanges
Elite |
16-Dec-2021 09:16
Yells: "No price is too low for a bear or too high for a bull" |
||||
|
x 0
x 0 Alert Admin |
|
||||
| Useful To Me Not Useful To Me | |||||
|
GoodLearner
Senior |
16-Dec-2021 09:14
|
||||
|
x 0
x 0 Alert Admin |
I queue at 0.004 and 0.003 unless the cloud is cleared.
|
||||
| Useful To Me Not Useful To Me | |||||
|
SureStrike
Veteran |
16-Dec-2021 08:57
|
||||
|
x 0
x 0 Alert Admin |
Yup.
|
||||
| Useful To Me Not Useful To Me | |||||
|
MakeChanges
Elite |
16-Dec-2021 08:56
Yells: "No price is too low for a bear or too high for a bull" |
||||
|
x 0
x 0 Alert Admin |
like what price? 0.001?
|
||||
| Useful To Me Not Useful To Me | |||||
|
GoodLearner
Senior |
16-Dec-2021 08:53
|
||||
|
x 0
x 0 Alert Admin |
the uncertainty remained if not elevated! Queue at lower price. | ||||
| Useful To Me Not Useful To Me | |||||
|
MakeChanges
Elite |
16-Dec-2021 08:07
Yells: "No price is too low for a bear or too high for a bull" |
||||
|
x 0
x 0 Alert Admin |
QT VASCULAR LTD. (Company Registration No. 201305911K) (Incorporated in the Republic of Singapore) FURTHER UPDATE ON EXTRAORDINARY GENERAL MEETING CALLED BY REQUISITIONING SHAREHOLDERS ON 15 DECEMBER 2021 TO REMOVE ALL DIRECTORS 1. The Board of Directors (&ldquo Board&rdquo ) of QT Vascular Ltd (" Company" ) refers to its announcements dated 8 December 2021, 11 December 2021 and 13 December 2021 in relation to the extraordinary general meeting (&ldquo EGM&rdquo ) called by Mission Well Limited and Tansri Saridju Benui (&ldquo Requisitioning Shareholders&rdquo ) on 15 December 2021 to remove all Directors of the Company. Capitalised terms used herein, unless otherwise defined, shall have the meanings ascribed in the aforesaid announcements. 2. The Company understands that the Requisitioning Shareholders have proceeded with the EGM today at 9.30am, notwithstanding the concerns previously raised by the Company. 3. The Company would reiterate for the benefit of all Shareholders that the resolutions proposed at the EGM to remove all the Directors is flawed, and would cause the Company to be in breach of Article 83 of its Constitution and Section 145 of the Companies Act (Cap. 50 of Singapore). 4. The Directors have therefore been advised by the Company&rsquo s counsel that to the extent the aforesaid resolutions breach constitutional and statutory requirements which the Company is subject to and must comply with, the Directors remain incumbent and are entitled to continue acting on behalf of the Company. 5. The Company also expresses its disappointment with the Requisitioning Shareholders proceeding with the EGM on 15 December 2021 despite the breach of constitutional and statutory requirements highlighted by the Company. 6. The Company will continue to make the necessary announcements to update shareholders on material developments as and when appropriate. 7. SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY. SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO READ ANY ANNOUNCEMENTS BY THE COMPANY CAREFULLY. THEY SHOULD CONSULT THEIR STOCKBROKERS, BANK MANAGERS, SOLICITORS, ACCOUNTANTS, TAX ADVISORS OR OTHER PROFESSIONAL ADVISORS IF THEY ARE IN ANY DOUBT AS TO THE ACTIONS THEY SHOULD TAKE. |
||||
| Useful To Me Not Useful To Me | |||||
|
sklong138
Elite |
16-Dec-2021 06:19
|
||||
|
x 0
x 0 Alert Admin |
Bro, the extract of the business.com.sg news as shown below is interesting. The additional shares issued by the incumbent directors recently represents some 10.3 percent of QT enlarged shares capital, it implies that if MW wants to call for a 3th EGM to appoint their new Directors, it would mean thar MW will have to up their stake of at least more than 10.3 percent which amounting of more than 200 million of shares via acquisition of shares through open market to counter the votes against the incumbent directors. Will MW carry out such action? We shall wait & see. Extract from business.com.sg :- " The incumbent directors also plan to issue new shares to repay US$1 million of debt to creditors, including former chief executive Eitan Konstantino as well as 2 entities: MDIE and Emerald Apex." " The additional shares would represent 10.3 per cent of QT Vascular' s enlarged share capital, and could tip the balance of voting power against the requisitioning shareholders who are trying to oust the existing board."
|
||||
| Useful To Me Not Useful To Me | |||||